Hanson Pharmaceuticals announced on September 27 that the European Commission announced the withdrawal of the marketing license for ametinib mesylate tablets in the European Union. The product was approved for sale by the European Commission on February 12, 2026, and the overseas product name is Aumseqa®. According to the announcement, the revocation stemmed from AstraZeneca's lawsuit against the European Commission. The European Commission's reason for withdrawing the marketing license for ametinib was not an issue with the quality, safety, or efficacy of the drug itself, but simply a procedural issue in the regulatory evaluation process. Hanson Pharmaceuticals's announcement mentioned that after this cancellation, the company will re-launch an application for ametinib's marketing license in the EU as soon as possible, and will remain firm in its innovation and internationalization strategy. According to information, there is currently no actual sales of this product overseas, and the marketing approval obtained by ametinib in the UK in 2025 is still valid, and market expectations have no impact on Hanson Pharmaceuticals' performance.

Zhitongcaijing · 1d ago
Hanson Pharmaceuticals announced on September 27 that the European Commission announced the withdrawal of the marketing license for ametinib mesylate tablets in the European Union. The product was approved for sale by the European Commission on February 12, 2026, and the overseas product name is Aumseqa®. According to the announcement, the revocation stemmed from AstraZeneca's lawsuit against the European Commission. The European Commission's reason for withdrawing the marketing license for ametinib was not an issue with the quality, safety, or efficacy of the drug itself, but simply a procedural issue in the regulatory evaluation process. Hanson Pharmaceuticals's announcement mentioned that after this cancellation, the company will re-launch an application for ametinib's marketing license in the EU as soon as possible, and will remain firm in its innovation and internationalization strategy. According to information, there is currently no actual sales of this product overseas, and the marketing approval obtained by ametinib in the UK in 2025 is still valid, and market expectations have no impact on Hanson Pharmaceuticals' performance.